Literature DB >> 8061825

High-performance liquid chromatographic method for the enantioselective analysis of mefloquine in plasma and urine.

L Wallén1, O Ericsson, I Wikström, U Hellgren.   

Abstract

An HPLC method for analysis of the enantiomers of the antimalarial drug mefloquine is presented. A complete resolution of (-)-(11S,2'R) and (+)-(11R,2'S) erythro-mefloquine from plasma and urine was obtained on a commercial AGP column. Mefloquine enantiomers were detected by UV at 222 nm. The separation factor (alpha) at +20 degrees C was 1.50. The limit of determination (coefficient of variation 4.0%) for the enantiomeric ratio (11S,2'R)/(11R,2'S) is 15:1 at a total mefloquine concentration of 1.6 mM.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061825     DOI: 10.1016/0378-4347(94)00027-1

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  3 in total

1.  Crystal structure of (-)-mefloquine hydrochloride reveals consistency of configuration with biological activity.

Authors:  Jean M Karle; Isabella L Karle
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors.

Authors:  Mahadeo A Sukhai; Swayam Prabha; Rose Hurren; Angela C Rutledge; Anna Y Lee; Shrivani Sriskanthadevan; Hong Sun; Xiaoming Wang; Marko Skrtic; Ayesh Seneviratne; Maria Cusimano; Bozhena Jhas; Marcela Gronda; Neil MacLean; Eunice E Cho; Paul A Spagnuolo; Sumaiya Sharmeen; Marinella Gebbia; Malene Urbanus; Kolja Eppert; Dilan Dissanayake; Alexia Jonet; Alexandra Dassonville-Klimpt; Xiaoming Li; Alessandro Datti; Pamela S Ohashi; Jeff Wrana; Ian Rogers; Pascal Sonnet; William Y Ellis; Seth J Corey; Connie Eaves; Mark D Minden; Jean C Y Wang; John E Dick; Corey Nislow; Guri Giaever; Aaron D Schimmer
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.